COMPOSITIONS AND METHODS FOR THE TREATMENT OF UREA CYCLE DISORDERS AND GOUT

摘要

The disclosures herein provide compounds of Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI and Formula VII or its pharmaceutical acceptable compositions and salts, as well as polymorphs, enantiomers, stereoisomers, solvates, and hydrates thereof. The pharmaceutical compositions may be formulated for oral administration, delayed release or sustained release, transmucosal, syrup, topical, parenteral administration, injection, subdermal, oral solution, rectal administration, nanoparticle, buccal administration or transdermal administration. Such compositions may be used to treatment of urea cycle disorders and gout or its associated complications.

主权项

1. A compound of Formula I: or salts, pharmaceutically acceptable salts, hydrates, solvates, crystals, esters, enantiomers, or stereoisomers thereof, or mixtures thereof, wherein: R1 independently represents CD3, CD2, CD3CO, NULL,and
R2 independently represents NULL, n is independently 1, 2, 3, 4 or 5; a is independently 2,3 or 7; each b is independently 3, 5 or 6; e is independently 1, 2 or 6; c and d are each independently H, D, —OH, —OD, C1-C6-alkyl, —NH2 or —COCH3.